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ABSTRACT

Type-4-cAMP-phosphodiesterases (PDE4s) are a group of isoenzymes that
hydrolyze the second messenger cyclic adenosine monophosphate (cAMP). PDE4
inhibitors have many therapeutic uses including reducing inflammation, however, they
also have side effects like nausea and emesis, which have diminished the clinical utility
of PDE4 inhibitors. When administered to mice, PDE4 inhibitors have been shown to
cause hypothermia. Given that nausea and emesis in humans are also associated
hypothermia, this project served to determine whether PDE4 inhibitor-induced
hypothermia may represent a correlate of nausea and/or emesis in mice. To this end, the
current literature was screened for articles that explore nausea, emesis and hypothermia
in any species, and experiments were performed to test the validity of the nausea to
hypothermia correlate. The PDE4 family comprises 4 subtypes, PDE4A-D, each playing
unique roles in the body. Body temperature was measured in mice deficient of individual
PDE4 subtypes. The results show that baseline body temperature was not different in any
of the PDE4KO (knockout) animals, and treatment with a PDE4 inhbitor induced
substantial hypothermia in the WT and KO mice. Together, these data suggest that
inactivation of any single PDE4 subtype does not induce hypothermia, and that PAN-
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PDE4 inhibitors thus induce hypothermia via the concurrent inhibition of multiple PDE4
subtypes. If hypothermia in mice indeed represents a useful correlate of nausea in
humans, then PDE4 inhibitor-induced nausea and emesis must also result from the
simultaneous inhibition of multiple PDE4 subtypes, and inhibitors selective for specific
PDE4 subtypes should be free of these side effects.
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INTRODUCTION

Role of the second messenger cAMP in cell-cell signaling
cAMP is a key signaling molecule found in all cells of the body and serves to
transduce the action of an extracellular signal into the appropriate cellular response. The
process for creating, using, and degrading cAMP is part of a process called a signal
transduction pathway. (Yan et al., 2016). Extracellular signals that eventually signal via
cAMP production include hormones (adrenaline, glucagon, and prostaglandins) or other
molecules (neurotransmitters or pharmaceuticals) bind to a receptor on the cell membrane
of the target cell and triggers a conformational change in the receptor (Figure 1). For
cAMP signaling, these receptors are G Protein-Coupled Receptors (GPCR) that
subsequently activate heterotrimeric G-proteins that are comprised of three subunits – a,
b, and g. There are three types of a-subunits, Gs (stimulatory for adenylyl cyclase)
protein, or Gi (inhibitory) protein, and Gq. Interaction with the activated receptor causes
the GPCR’s subunits to split and the a-subunit to detach and travel along the cell
membrane where it will bind to an enzyme, adenylyl cyclase (AC), in the cell membrane
and activates it to increase production of cAMP (Conti et al., 2003). Some molecules
bind to the GPCR and trigger the release of the Gi subunit, which inhibits adenylyl
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cyclase and therefore inhibits the production of cAMP. The third subunit, Gq, does not
play a role in cAMP production.

Figure 1. Cellular mechanisms of cAMP and PDE and its downstream effectors. Figure
depicting the key players in the production and degradation of cyclic adenosine
monophosphate (cAMP). A G-Protein coupled receptor on the cell membrane receives an
extracellular signal (orange triangle), leading to the release of the stimulatory subunit Gs and
the subsequent downstream activation of adenylyl cyclase and the production of cAMP from a
molecule of adenosine triphosphate (ATP). Gi can also be activated to inhibit the production of
cAMP. cAMP has 3 downstream effectors – protein kinase A (PKA), which phosphorylates
and regulates many proteins, cyclic nucleotide gated channels (CNG) and the exchange protein
activated by cAMP (EPAC) which is a regulator of RAP signaling. Phosphodiesterases (PDEs)
are then activated and hydrolyze the cAMP to inactivate it.

Upon activation, AC converts adenosine triphosphate (ATP) into cAMP. The cAMP
continues on to stimulate 3 downstream effectors: protein kinase A (PKA), which
phosphorylates myriad proteins, cyclic nucleotide gated channels (CNG) and the
exchange protein activated by cAMP (EPAC) which is a regulator of RAP signaling
(Conti et al., 2003).
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The superfamily of mammalian cyclic nucleotide phosphodiesterases
In order to halt the processes that were activated by cAMP, the molecules must be
degraded or otherwise broken down to be rendered inactive. This job falls to a class of
enzymes called phosphodiesterases (PDEs). Twenty-one genes encoding for PDEs have
been found in the human genome, and they can be subdivided into 11 families – PDE1PDE11 (Richter et al., 2013). These enzymes are substrate-specific for either cAMP,
cGMP (cyclic guanosine monophosphate), or both. They degrade these nucleotides with
different velocities and specificities. There are 3 enzymes that are exclusively selective
for cAMP – PDE4, PDE7, and PDE8. Three more are exclusively selective for cGMP –
PDE5, PDE6, and PDE9. The remaining PDE families degrade both cAMP and cGMP to
various extents.
All mammalian PDEs have similar sequence homology with a relatively
conserved catalytic domain at the carboxy terminus (Figure 2) (Conti et al., 2003). This
catalytic domain primarily determines substrate specificity and inhibitor sensitivity, as
these enzymes experience competitive inhibition where their substrates compete with
their inhibitors. The regulatory domains at the N-terminus of each family are different
and are involved in regulation of enzyme activity through binding of small regulatory
molecules such as phosphatidic acid, calcium calmodulin, or cGMP, or through
phosphorylation. In addition, the domains at the amino terminus are involved in
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subcellular targeting that allows for the recruitment of the enzymes to various
compartments of the cell through interaction of various lipids or proteins.

Figure 2. The superfamily of phosphodiesterases and their structures.
Figure depicting the organization and structure of the 11 phosphodiesterase families.
On the left, the 11 PDE families is listed. To the right are 21 subtypes, A, B, C, or D.,
that belong to each family. Shown next are the substrates of each family, either cAMP
or cGMP or both. Next is the domain structure, where the domains are indicated by
barrels connected by black lines. The regulatory domains are shown with their
respective binding sites which regulate the enzyme’s activity, and all PDE families
have a conserved catalytic domain on the C-terminus that determines substrate kinetics
and inhibitor sensitivity.

The PDE family that will be focused on in this project is PDE4. The PDE4 family
is one of the 3 that selectively hydrolyze cAMP, and is comprised of 4 subtypes –
PDE4A, 4B, 4C, and 4D – all of which have so far been found to play unique and non-
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overlapping roles in cells (Richter et al., 2013). PDE4 is the both the largest and the most
widely expressed PDE4 family. As PDE4 of some subtypes can be found in virtually
every cell in the body, it is unsurprising that the development of a selective PDE4
inhibitor would be a breakthrough in the medical treatment of several pathologies.

Targeting PDE4 for therapeutic benefits
Given cAMP’s role in this pathway as a second messenger, it is clear to see how
targeting its degradation with more specific inhibitors could play a key role in developing
therapeutics. PDE4 inhibitors have been found in human and animal studies to possess
several promising therapeutic benefits, such as anti-inflammatory effects and improved
cognition and memory. Figure 3 shows that PDE4 inhibitors are being develop and tested
for dozens of inflammatory diseases. In the case of cognition and memory, the PDE4
inhibitor Roflumilast was shown to improve cognition in rodents when given in nonemetic doses (Vanmierlo et al., 2016). It was also shown to improve delayed word recall
in both older humans and in young adults when given at low doses (Blokland et al., 2019;
Van Duinen et al., 2018). However, despite billions of dollars of research investments
and 30 years of research, the clinical success of PDE4 inhibitors has been limited. Only
three PDE4 inhibitors have been approved by the FDA, and they’re not that widely used,
especially when compared to how widely expressed PDE4 is in nearly every human cell.
This is because of their adverse side effects that limit their clinical use – nausea, emesis,
weight loss, and other gastrointestinal issues.
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There are currently only three FDA approved PDE4 inhibitors – roflumilast,
apremilast, and Arcutis. Roflumilast is currently FDA approved to treat the airway

inflammation in individuals with COPD (Wedzicha et al., 2016; Zhang et al., 2018).
Apremilast has been used as an anti-inflammatory drug and has been FDA approved to
treat plaque psoriasis (Gooderham and Papp, 2015). The third FDA approved PDE4
inhibitor is Arcutis, which is a topical cream that is used to treat plaque psoriasis and
atopic dermatitis.
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Figure 3. Diseases targeted by PDE4 inhibition. PDE4 inhibitors like Rolipram, Apremilast,
and Roflumilast act in numerous systems of the body, including the nervous, respiratory,
digestive, skeletal, and integumentary systems. They are used to treat diseases like
neuroinflammation, inflammatory airway diseases, ankylosing spondylitis, psoriasis, atopic
dermatitis, and rheumatoid arthritis (Li et al., 2018).

Identifying the role of individual PDE4 isoforms to maximize therapeutic benefits
In order to maximize the clinical utility of PDE4 inhibitors, it’s important to
identify the role of the individual isoforms (PDE4A-D) in order to be able to target one or
any combination of them to combat disease. However, there are currently no PDE4
isoform-selective inhibitors to be used in experimentation, which means only nonselective PDE4 inhibitors (PAN-PDE4 inhibitors) have been generated for use in humans,
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and it is difficult to study nausea in any animal. These PAN-PDE4 inhibitors come with
significant side effects, including nausea, emesis (or the feeling of having to vomit),
weight loss, and gastrointestinal problems in both humans and mice (Li et al., 2018).
These side effects happen with enough frequency that it drastically diminishes the clinical
utility of the PAN-PDE4 inhibitors that have been developed. The individual isoform(s)
involved in causing these side effects is still unknown, but it has been established that
these isoforms play unique and non-overlapping roles in human cells. This was made
possible by the generation of and experimentation on knockout (KO) mice for each
isoform and the knockdown of each isoform in experimental cells. The experimentation
on these PDE4KO mice is crucial to understanding the role of each isoform. If the
therapeutic effects could be targeted while bypassing any major side effects, the drugs
would be significantly more clinically useful and effective.

Treatment with PAN-PDE4 inhibitors induces hypothermia in mice
Previous experimental data shows that treatment with PDE4 inhibitors causes a
severe drop in body temperature in mice leading to hypothermia (Figure 4) (McDonough
et al., 2020). The body temperatures of mice in this experiment were recorded using an
infrared thermometer at the sternum of the mouse. After intraperitoneal injection of 5
mg/kg of the PAN-PDE4 inhibitor Piclamilast, the most drastic drop in body temperature
is seen within the first 10-15 minutes, where the body temperature of the mouse drops
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Figure 4. Treatment with the PDE4 inhibitor Piclamilast induces hypothermia in
mice.
Shown is a time course of changes in body temperature of mice injected with the PDE4
inhibitor Piclamilast/RP73401 (5 mg/kg; i.p.) as well as solvent- and non-injected
controls. Body temperatures were measured at the sternum of mice using an infrared
thermometer. Data represent the mean ± SEM of n ≥ 8 animals. The body temperature
of Piclamilast-treated mice is statistically different (p<0.001) from the solvent- or noninjection controls as determined by one-way ANOVA with Bonferroni’s post hoc test.

dramatically into hypothermic levels. The lowest body temperature is seen 30 minutes
post-injection with a recovery of normal body temperature within 6 hours of injection.

The importance of establishing a quantifiable correlate for nausea in animals
Given that nausea and emesis in humans are also associated with signs of
hypothermia, such as cold sweats and clammy hands, this research project served to
determine whether PDE4 inhibitor-induced hypothermia may represent a useful correlate
of nausea and/or emesis in mice for research purposes. Should a strong correlate for
nausea (the main side effects hindering the clinical use of PDE4 inhibitors) and
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hypothermia (a quantifiable symptom in PDE4KO mice) be identified, it would allow for
animal models to be implemented that would aid in identifying the mechanisms behind
the adverse side effects for drugs of all types. It would aid in the development of a
selective PDE4 inhibitor that would be able to be translated into a clinical application to
treat inflammation and other diseases without compromising the overall health of the
patient.

Special note: Given that the University’s response to the COVID-19 pandemic prevented
on-campus experimentation for nearly the entirety of 2020, this project was initially
approached with literature research. This research served to answer what animals models
have been established and whether hypothermia may serve as a useful model for nausea.
With the reopening of campus, the literature-based findings were extracted and
implemented into in-lab experiments, performed by myself and other members of the lab,
as a team effort to test the hypotheses developed through the literature research.
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PROJECT HYPOTHESIS AND AIMS
Overall Hypothesis
We hypothesize that PDE4 inhibitor-induced hypothermia may represent a useful
correlate of nausea in mice and may be used to explore its molecular mechanism and the
specific PDE4 isoforms involved.
Aims
Literature research
1. Identify the molecular mechanisms that drive nausea and emesis and distinguish
them.
2. Identify adverse effects and the prevalence of those effects.
3. Identify and address the prior attempts to identify PDE4 subtypes to correlates of
emesis.
4. Address the difficulty in assessing nausea and emesis in animals.
5. Delineate other paradigms in humans and animals where nausea is associated with
hypothermia.
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Experimental Approaches
6. Perform experiments to elucidate the role of individual PDE4 subtypes in PDE4
inhibitor-induced hypothermia.

12

MATERIALS AND METHODS

Literature Review Approach:

Figure 5. Literature Review Approach
Figure outlining the approach taken to select literature for the literature-based portion
of this project. The databases PubMed, Google Scholar, and EBSCO were used to
13

(continued from previous page) search for literature with the keywords “PDE4
inhibitor” and “nausea or emesis", “PDE4 inhibitor and hypothermia”, “Nausea and
Hypothermia”. Publication dates were restricted to between 1980-2021. The screening
criteria required that the title or abstract must contain one set of the keywords and 355
papers met this criteria. These papers were screened thoroughly for relevant material.
The inclusion criteria required the mention of PDE4 or PDE4 inhibition inducing
nausea, emesis or hypothermia; nausea or emesis and hypothermia being recorded
concurrently; previous correlates or paradigms established with nausea, emesis, or
hypothermia. Forty-two studies met one or multiple inclusion criteria. Twenty studies
mentioned the effect of PDE4 inhibition and nausea, emesis, or hypothermia. Eleven
studies mentioned the concurrent presence of nausea, emesis, or hypothermia. Eleven
studies mentioned previous models used for nausea, emesis, or hypothermia.

Drugs
Piclamilast (RP73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4methoxybenzamide), Rolipram (4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2one), Roflumilast (3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4(difluoromethoxy)benzamide), Clonidine (N-(2,6-dichlorophenyl)-4,5-dihydro-1Himidazol-2-amine) and Yohimbine (methyl (1S,15R,18S,19R,20S)-18-hydroxy1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate) were from
Cayman Chemical (Ann Arbor, MI), from Millipore Sigma (St. Louis, MO, USA) was
obtained from Santa Cruz Biotech (Santa Cruz, CA). All drugs were initially dissolved in
DMSO, subsequently diluted into phosphate-buffered saline (PBS), pH 7.4, containing
final concentrations of 5% DMSO and 5% Cremophor EL (Millipore Sigma, St. Louis,
MO) and were applied by intraperitoneal (i.p.) injection (100 µl per 20 g body weight)
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Animals
Wildtype C57BL/6 mice for experimentation were generated in-house using
breeders obtained from Charles River Laboratories (Wilmington, MA). Mice deficient in
PDE4A, PDE4B and PDE4D were generated by Drs. S.-L. Catherine Jin and Marco
Conti (Stanford University, CA) and kindly distributed via the Mutant Mouse Resource
and Research Centers (MMRRC, http://www.mmrrc.org, PDE4A stock ID# 034793UCD, PDE4B stock ID# 034682-UCD, PDE4D stock ID# 034588-UCD) of the
University of California at Davis. PDE4C knockout mice (Pde4ctm1.1(KOMP)Wtsi/J) were
generated by the National Institutes of Health (NIH) Knockout Mouse Program
(KOMP; www.komp.org) and kindly distributed via the KOMP repository at the
University of California at Davis. Additional details are available on the website of the
Mutant Mouse Regional Resource Centers (MMRRC; http://www.mmrrc.org; Stock
number 049025-UCD). All mice were maintained on a C57BL/6 background and group
housed four mice per cage with ad libitum access to food and water in a temperaturecontrolled (22-23°C) vivarium with a 12-h light/dark cycle. Adult mice ≥10 weeks of age
and ≥18 g of body weight were used for experimentation by equally and randomly
dividing cage littermates into experimental groups. Experimenters were blinded to the
identity of the injected drugs until data acquisition and analyses were completed. All
experiments and procedures were conducted in accordance with the guidelines described
in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health,
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Bethesda, MD, USA) and were approved by the University of South Alabama
Institutional Animal Care and Use Committee.

Measurement of Core Body Temperature
Core body temperature was measured as described previously (McDonough et al.,
2020) using a thermocouple thermometer (MicroTherma 2T) with mouse rectal probe
(RET-3), both from Braintree Scientific (Braintree, MA), following the manufacturers’
instructions (Figure 6).

Figure 6. Illustration of the approach to measure body temperature of mice using
a rectal thermocouple probe.
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Hypothermia or Body Temperature Experiment
Mice were selected by the principal investigator (PI) by genotype and organized
into a Microsoft Excel table with the genotypes of each mouse blank to keep the
researcher blinded to each mouse’s genotype to prevent researcher’s bias. The researcher
used this information to retrieve the appropriate mice and weighed each mouse to
confirm body weight for drug dosage. The drug was delivered via intraperitoneal
injection at time = 0 minutes. The rectal temperature of each mouse was recorded at time
= -30 minutes, -1 min, 30 min, 60 min, 90 min, 120 min, and 150 min.

Duration of Ketamine/Xylazine Anesthesia
The duration of Ketamine/Xylazine-induced anesthesia was measured as
described previously (Robichaud et al., 2002b). In short, mice were anesthetized with the
combination of xylazine (10 mg/kg) and ketamine (80 mg/kg) administered by
intraperitoneal injection. Upon loss of righting (2-3 min), the mice were then placed in
dorsal recumbency and the time to first righting was measured. Experiments were ended
at 120 min after Ketamine/Xylazine injection and animals that did not right themselves
by that time were recorded as 120 min. To probe the effect of drug treatment, the α2adrenoceptor antagonist Yohimbine (1 mg/kg), the PAN-PDE4 inhibitors Rolipram (0.01,
0.2 or 1 mg/kg) or RP73401 (5 mg/kg), or mock/solvent control were injected (i.p.) into
anesthetized mice at 10 min after Ketamine/Xylazine administration.
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Graphing and Analysis of Data
All data are expressed as the mean ± SEM and n numbers indicate the number of
individual animals assessed and are represented by individual dots in the scatter plots.
The GraphPad Prism 9 software (GraphPad Software Inc, San Diego, CA, USA) was
used to perform statistical analyses. Mann-Whitney test with 95% confidence interval
was used to compare two treatment groups and Kruskal-Wallis followed by Dunn’s post
hoc test was used to determine differences between more than two treatment groups.
Time courses were analyzed using two-way ANOVA with Bonferroni’s post hoc test.
Statistical differences are indicated as # (not significant; p>0.05), * (p<0.05), **
(p<0.01), and *** (p<0.001).
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RESULTS
Literature Review to assess the potential of PDE4 inhibitor-induced hypothermia as
a correlate of nausea/emesis in mice
To determine whether PDE4 inhibitor induced hypothermia in mice may represent a
useful correlate of nausea and/or emesis in these animals, detailed systematic literature
searches were performed to answer the following specific questions:
1. What are nausea and emesis and how are they distinguished?
2. What is the prevalence of nausea and emesis after PDE4 inhibitor administration?
3. What correlates of nausea and emesis have been used in animals?
4. Is hypothermia associated with nausea and emesis in humans and/or animals?
5. Has hypothermia been used as a correlate of nausea/emesis in animals?
If the pathway and specific cellular mechanisms that cause emesis can be pinpointed and
subsequently excluded from being targeted by PAN-PDE4 inhibitors, then a developed
drug can be used in a much wider range of patients with less side effects. The main side
effects that affect the clinical utility of PAN-PDE4 inhibitors are nausea and emesis. By
finding a correlate between nausea and hypothermia, the difficulties in assessing nausea
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and/or emesis in animals can be overcome and measured in a quantifiable way, leading to
the development of a targeted drug therapy with minimal side effects.

Nausea and emesis are mechanistically not the same thing
While nausea and emesis frequently occur together, the two are not necessarily
the same thing distinguished only by severity and the molecular mechanisms causing
these symptoms, while complex, are not identical. Nausea is characterized by the feeling
or perception of discomfort in the gastric region (Horn, 2014). It is associated with
changes in both the autonomic and central nervous systems, as well as changes in
electrogastrogram results, which records electrical activity of the digestive organs (Stern
et al., 2011). Conversely, emesis is the action of vomiting, which can be defined as
retching in an attempt to expel or the expulsion of stomach contents. It consists of a preejection phase (which can include severe nausea), retching, and ejection (Navari, 2018).
Emesis is triggered by a neural reflex (Elwood et al., 2010), which can be linked to the
area postrema in the brainstem. The area postrema is classified as the emesis center of the
brain, is located on the medulla oblongata, and is unique as it is not contained by the
blood-brain barrier (Miller and Leslie, 1994). This allows it to detect any toxins in the
blood and in the cerebrospinal fluid that the body needs to expel through vomiting.
Emesis is, after all, an evolutionary response designed to keep the body safe from
ingesting toxins (Popa et al., 2019). When the emetic toxins are detected in the stomach
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or in the bloodstream, the emetic reflex (retching) is triggered in order to expel the toxins
from the body.
Recall that PDE4 inhibitors selectively degrade the second messenger cAMP,
which are commonly linked to specific receptors in the area postrema. When various
emetic drugs were given to dogs, a consistent threshold needed to induce vomiting was
found. When given a PDE4 inhibitor, the same emesis threshold was invoked using lower
concentrations than when no PDE4 inhibitor was given (Carpenter et al., 1988). This
shows that cAMP does play a crucial role in triggering the emetic reflex. Further studies
have shown a relationship between the PDE4D isoform and nausea and emesis. This
stems from the discovery that PDE4D is found in higher concentrations in the area
postrema (Lamontagne et al., 2001). Furthermore, PDE4D deficient mice were found to
be less susceptible to the emetogenicity, or the affinity to produce an emetic response, of
PDE4 inhibitors, suggesting that the PDE4D subtype may play a role in mediating the
emetic reflex (Robichaud et al., 2002b).

Nausea and emesis are the main adverse effects and nausea is much more frequent
than emesis and thus represents the main issue
As shown, nausea and emesis are distinct from each other and are therefore
treated differently. One can feel nauseous without ever being emetic, and, more rarely,
one can be emetic and not feel nauseous. For example, when one feels nauseous, it is
normal that they won’t experience emesis. This is true for conditions like motion
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sickness, where a person can feel nauseous, but not so much that they experience emesis.
Since nausea and emesis are two distinct phenomena, their prevalence in clinical settings
is also distinct. Nausea is more prevalent than emesis in most cases, especially in side
effects of drugs. In one clinical study that used roflumilast (a PDE4 inhibitor) for asthma,
the prevalence of emesis was 5.6% whereas the prevalence of nausea was much higher at
28.7% (Chervinsky et al., 2015). This is significant because a population that is
prescribed a drug that causes nausea in nearly 30% of patients will be much less likely to
continue the drug, and demonstrates the need for a PDE4 selective inhibitor. In a study
testing apremilast (a PDE4 inhibitor), the prevalence of nausea and vomiting in the first
1-5 days was 7.4% and 0.8%, respectively. Between 6-112 days, the ratio was 8.9% and
3.2% , respectively (Cada et al., 2014). The high prevalence of PDE4 inhibitor-induced
side effects that cause discomfort to the patient greatly diminishes the clinical utility of
PAN-PDE4 inhibitors and further demonstrates the need for a PDE4 subtype-selective
inhibitor in order to extract the therapeutic effects from the adverse effects.

It is difficult to assess nausea/emesis in animals, particularly rodents
Nausea and emesis are difficult to quantifiably assess in animals, as many species
commonly used for research do not possess the ability to vomit, including the fly and
fish, as well as mammals like mice and rats. Rodents don’t have the mechanical
structures needed to vomit, although they do have a gag reflex that can cause a single
retch (Andrews and Horn, 2006; Horn et al., 2013). One study found that rats are
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incapable of experiencing emesis because they either lack the neuronal pathways to
coordinate emesis, or the emetic centers in the brain needed to vomit are degenerate.
They can, experience nausea, as shown by conditioned taste aversions produced by
emetic stimuli (Horn et al., 2013), however, it is hard to quantify in a mouse. Data for
these emetic drugs have been collected for species that do experience emesis, such as
dogs and musk shrews (Rudd et al., 2015) (Figure 7).

Figure 7. Summary of the biological effects of the emetic agent Resiniferatoxin.
Resiniferatoxin (RTX) given subcutaneously in a range of species indicated by the
silhouette. RTX may cause undesirable effects (red) including emesis, genesis of
conditioned taste aversion (CTA), hypertension, stimulation of intense ano-genital
grooming and hypothermia. However, RTX also has the desirable effect of being a
broad-spectrum anti-emetic agent with the range of emetic stimuli affected shown on
the right hand side (green) (adapted from Rudd et al., 2015)
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There are a few behavioral animal models that have been traditionally viewed as a
sign that the animal is experiencing discomfort such as nausea, especially in animals that
can’t vomit, like rats and mice, but that didn’t show promise when applied in other
relevant ways. Pica, which is the ingestion of non-food materials, is used as a surrogate
measure for cisplatin-induced emesis in non-vomiting animals like rats. The findings for
this, however, were not consistent with mice nor musk shrews, which can vomit.
Therefore, this is not a strong correlate for emesis in mice (Liu et al., 2005; Yamamoto et
al., 2004).

Nausea is associated with hypothermia in multiple paradigms in humans and
animals
Nausea and emesis are associated with hypothermia in multiple paradigms in
humans and animals. These paradigms include motion sickness, drug or anesthesiainduced nausea, cold-induced nausea, and food poisoning.
One of the most commonly known is motion sickness. Both animals and humans
experience motion sickness which is known to induce nausea and emesis. While the
causes of motion sickness-induced hypothermia are still unknown, it is hypothesized to
be caused by cutaneous vasodilation, sweating, and thermogenesis (Nalivaiko et al.,
2014). In the case of cutaneous vasodilation, the blood vessels near the skin dilate,
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causing more heat to escape the body into the environment, which lowers the body
temperature, causing hypothermia in extreme cases. In animals such as rats and musk
shrews, hypothermia caused by motion sickness has been confirmed and used as a direct
correlate to nausea (Ngampramuan et al., 2014).
Another known link between hypothermia and nausea is evident in cases where
hypothermia is induced by a cold environment or extended contact with cold water. In
these cases, nausea and vomiting is a common side effect of moderate hypothermia
(Cheshire, 2016).
There are also several prodromal signs that are known to occur before emesis,
such as nausea and cold sweats (Horn, 2008). Most people have experienced this in
everyday life when they feel nervous or frightened and experience clammy hands and
cold sweats paired with nausea. In fact, cold sweats were scientifically linked to motion
sickness specifically as early as 1944 (Hemingway, 1944). Emesis has also been linked
to an increase in shivering and salivation (Navari, 2018), which compounds on the
evidence of emesis being linked to the sensation or manifestation of a lowered body
temperature. Further, a woman giving birth who was given intrathecal morphine was
hypothermic and had heavy sweating, as well as complaints of severe nausea and
vomiting, demonstrating this can be drug-induced as well (Sayyid et al., 2003).
Other examples of nausea are drug-induced and anesthesia-induced. An
antipsychotic used to treat schizophrenia, risperidone, is commonly known to cause
nausea and emesis and in some cases causes hypothermia (Perera and Yogaratnam,
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2014). Other drugs, like anesthesia, have also been found to have a link between
hypothermia and nausea. In patients who had undergone a cardiac procedure using
general anesthesia, the incidence of post-operative nausea and vomiting (PONV) was
27.2%. The incidence of hypothermia (body temperature <36 °C) during and/or after the
surgery was 44% (Goldfuss et al., 2019). Neuraxial opioids, given before or during
surgery as an analgesic, cause nausea and vomiting and have been associated with perioperative hypothermia (Yurashevich and Habib, 2019).

Prior attempts to identify PDE4 isoforms linked to correlates of emesis using
PDE4KO animals
In one experiment that attempted to discover which PDE4 subtype was involved in
causing emesis, PDE4B and PDE4D knockout mice were injected with an anesthesia
combination of xylazine/ketamine (Robichaud et al., 2002b). In this study, Robichaud
and colleagues reported that genetic ablation of PDE4D shortens the duration of
xylazine/ketamine-induced anesthesia in mice, thus mimicking the effects of treatment
with PAN-PDE4 inhibitors, whereas ablation of PDE4B did not. Further, they deduced
that treatment with PAN-PDE4 inhibitors had no further effects on the duration of
xylazine/ketamine-induced anesthesia in PDE4D-KO mice. Thus, the authors proposed
that inhibition of PDE4D, but not PDE4B, is responsible for mediating the emetic effects
of PAN-PDE4 inhibitors.
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This conclusion was achieved through the a2 adrenoceptor signaling pathway.
The researchers found that in ferrets, the ketamine/xylazine drug combination made them
emetic and also caused a shorter duration of anesthesia (Robichaud et al., 2001). Then,
they wanted to determine the relation with PDE4, so PDE4BKO and PDE4DKO mice
were injected with the anesthesia and their duration of anesthesia, or time to righting,
(Figure 8) was recorded.

Figure 8: Illustration of the approach to measure time to righting.
(A-C) Representative images illustrating the approach to measure “Time to righting”. Upon
induction of anesthesia and resulting loss of righting (~3 min after Ketamine/Xylazine injection),
the unconscious mice are placed on their backs (A). As the anesthetic effect of Ketamine/Xylazine
wears off and the animals awaken, the righting reflex, an automatic reaction to move the body in its
normal position, kicks in (B) and the mice turn onto their abdomen (C). The time from loss of
righting (A; ~3 min after Ketamine/Xylazine injection) to the time of first righting (C) is recorded.
From: https://pubmed.ncbi.nlm.nih.gov/33609559/

The xylazine component of the anesthesia is an a2 adrenoceptor agonist and caused a
duration of anesthesia between 30 – 40 minutes in the PDE4B mice (Figure 9). Next, the
mice were injected with an a2 adrenoceptor antagonist and known emetic agent, MK27

912, and the mice has a diminished duration of anesthesia. Further, when injected with a
PDE4 inhibitor, PMNPQ, the mice also had a shorter duration of anesthesia. This
suggests that PDE4 inhibitor, which is already known to be emetic, has a similar emetic
effect as the a2 adrenoceptor antagonist and thus a correlate was established between the
emetogenicity of the PDE4 inhibitor and duration of anesthesia.

Figure 9. Effect of MK-912 and PMNPQ on the duration of anesthesia induced by
ketamine/xylazine anesthesia.
Effect of MK-912 and PMNPQ on the duration of anesthesia induced by the
combination of xylazine (10 mg/kg) and ketamine (80 mg/kg) in PDE4D-deficient (a)
and PDE4B-deficient (b) mice (–/–) and their littermates (wild-type, +/+; heterozygote,
+/–). Fifteen minutes after the induction of anesthesia, mice were injected with MK912 (1 mg/kg, subcutaneously), PMNPQ (0.3 mg/kg, subcutaneously), or vehicle (PEG
60%). The duration of anesthesia was assessed by the return of the righting reflex.
Results are expressed as mean ± SEM. *Significantly different at P < 0.05 (Robichaud
et al., 2002b).
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Several receptor antagonists have been studied to test whether they can protect
against the emetic effect of PDE4 inhibitors and other emetic drugs. One of these, a-2adrenoceptor antagonists, have also been linked to emesis and vomiting through the
experiments by Robichaud and colleagues. This relationship was established when a
resistance to a-2-adrenoceptor anesthesia was found to be a correlate of emesis in mice.
When given an a-2-adrenoceptor antagonist like clonidine, PDE4 inhibitor-induced
emesis was prevented (Robichaud et al., 2002a).
Conversely, there are also treatments that have been successful in treating emesis, but
that have not been effective at preventing nausea in patients with cancer (Navari, 2018).
These treatments included 5-hydroxytryptamine type 3 receptor (5HT3 receptor)
antagonists, neurokinin-1 receptor (NK1 receptor) antagonists, and dexamethasone.
Finally, there are also treatments that have shown promising results in treating both
emesis and nausea. One treatment, olanzipine, has been shown to reduce nausea
symptoms as well as emesis in patients undergoing an emetic chemotherapy treatment
(cisplatin) (Navari et al., 2016). However, it is still unknown which receptor types are
primarily involved in these pathways.

Experiments to confirm the role of PDE4 subtypes in mediating emesis
Wild type and knockout mice of each PDE4 subtype were anesthetized with the
combination of xylazine and ketamine by intraperitoneal injection and their time to
righting was recorded (Figure 10). The PDE4A, PDE4B, and PDE4C KO and WT mice
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had similar sleep times. However, the PDE4DKO mice had a significantly shorter sleep
time than any of the other subtypes.

Figure 10. Genetic ablation of PDE4D, but not ablation of PDE4A, PDE4B or
PDE4C shortens the duration of Ketamine/Xylazine-induced anesthesia in mice.
Mice were anesthetized with the combination of xylazine (10 mg/kg) and ketamine (80
mg/kg) administered by intraperitoneal injection. The mice were then placed in dorsal
recumbency and the time to first righting was measured. Data represent the mean ±
SEM. Statistical analysis was determined using Mann-Whitney test with 95%
confidence interval and is indicated as * (p<0.05).

Treatment with PAN-PDE4 inhibitors mimics the effects of α2-adrenoceptor
antagonism on the duration of Ketamine/Xylazine-induced anesthesia in mice
In order to confirm the claims set forth by Robichaud and colleagues, the time to righting
was measured in mice was recorded after injection of PAN-PDE4 inhibitors, Rolipram
and RP73401, and the α2-adrenoceptor antagonist yohimbine (Figure 11). First, mice
were anesthetized via an intraperitoneal injection of a combination of 10 mg/kg xylazine
and 80 mg/kg ketamine. Ten minutes later, the mice were injected intraperitoneally with
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Yohimbine (1 mg/kg), Rolipram (1 mg/kg), RP7301 (5 mg/kg), or solvent control (PBS
containing 5% DMSO and 5% Cremophor EL). The mice were then place in dorsal
recumbency and their time to righting was recorded. The mice injected with Yohimbine
were found to experience a significant decrease in time to righting, as well as those
injected with each PDE4 inhibitor.

Figure 11. Treatment with PDE4 inhibitors mimics the effects of α2-adrenoceptor
antagonism on the duration of Ketamine/Xylazine-induced anesthesia in mice.
Mice were anesthetized with the combination of xylazine (10 mg/kg) and ketamine (80
mg/kg) administered by intraperitoneal injection. Ten minutes later, the animals were
injected intraperitoneally with the α2-adrenoceptor antagonist Yohimbine (1 mg/kg),
the PAN-PDE4 inhibitors Rolipram (1 mg/kg) or RP73401 (5 mg/kg), or solvent
control (PBS containing 5% DMSO and 5% Cremophor EL). The mice were then
placed in dorsal recumbency and the time to first righting was measured. Data
(continued from previous page) represent the mean ± SEM. Statistical analysis was
determined using Kruskal-Wallis followed by Dunn’s post hoc test and is indicated as
* (p<0.05).
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Experiments to elucidate the role of individual PDE4 subtypes in PDE4 inhibitorinduced hypothermia
As shown in the introduction, PAN-PDE4 inhibitors induce dramatic, rapid onset
hypothermia in mice within the first 30 minutes of injection. In order to determine which
subtypes are involved in PDE4 inhibitor-induced hypothermia, the rectal temperature of
WT and PDE4KO mice of each subtype were recorded after intraperitoneal injection of
the solvent in one group and the other with the PAN-PDE4 inhibitor RP73401/Piclamilast
at 5 mg/kg (Figure12). After solvent injection (grey bars), the body temperature of mice
deficient in PDE4A (4AKO), PDE4B (4BKO), PDE4C (4CKO) or PDE4D (4DKO) was
not different than that of wildtype (WT) mice. Moreover, treatment with the PAN-PDE4
inhibitor RP73401 (red bars) induced a significant hypothermia compared to solvent
controls (grey bars) in all genotypes.
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Figure 12. PDE4 inhibitor-induced hypothermia results from the concurrent
inactivation of multiple (at least two) PDE4 subtypes.
The core body temperature of mice was measured using a rectal probe thermometer at
30 min after i.p. injection of the PAN-PDE4 inhibitor RP73401/Piclamilast (5 mg/kg)
or solvent control. After solvent injection (grey bars), the body temperature of mice
deficient in PDE4A (4AKO), PDE4B (4BKO), PDE4C (4CKO) or PDE4D (4DKO)
was not different than that of wildtype (WT) mice. Moreover, treatment with the PANPDE4 inhibitor RP73401 (red bars) induced a significant hypothermia compared to
(continued from previous page) solvent controls (grey bars) in all genotypes. Data
represent the mean ± SEM. Statistical significance was determined using one-way
ANOVA with Tukey’s post hoc test and is indicated as * (p < 0.05).

Experiments to determine the role of α2-adrenoceptor signaling on hypothermia
In order to determine the link between hypothermia and α2-adrenoceptor signaling
on hypothermia, mice were injected with an α2-adrenoceptor agonist, clonidine, and their
body temperatures were recorded 30 minutes post-injection (Figure 13A). As dosages of
clonidine administered increased (0.04 mg/kg, 0.2 mg/kg, and 1 mg/kg), the mice
experienced a more drastic drop in body temperature. The same experiment was repeated
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with an α2-adrenoceptor antagonist, yohimibine (1 mg/kg). Yohimibine was not found to
induce any significant drop in body temperature. In conclusion, the α2-adrenoceptor
agonist clonidine induced hypothermia whereas the α2-adrenoceptor antagonist
yohimbine did not induce hypothermia.
In order to deduce whether α2-adrenoceptor signaling has any protective effects
against PDE4 inhibitor-induced hypothermia, mice were injected with a solvent, an α2adrenoceptor agonist (Clonidine, 0.2 mg/kg and 1 mg/kg), and an α2-adrenoceptor
antagonist (Yohimbine (1 mg/kg) (Figure 13B). One hour later, the mice were injected
with 1 mg/kg of the PDE4 inhibitor Rolipram. Body temperature was recorded at time = 30 min, -1 min, 30 min, 60 min, 90 min, and 120 min. Clonidine in both dosages was
confirmed to cause a drop in body temperature, however α2-adrenoceptor agonism did not
protect or prevent from further PDE4 inhibitor-induced hypothermia. Yohimbine was
confirmed to not cause a drop in body temperature, however α2-adrenoceptor antagonism
did not protect or prevent from PDE4 inhibitor-induced hypothermia. In short, neither
agonism nor antagonism of the α2-adrenoceptor protects from PDE4 inhibitor-induced
hypothermia in mice.
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Figure 13. α2-adrenoceptor agonism induces hypothermia, but neither agonism
nor antagonism of α2-adrenoceptor protects from PDE4 inhibitor-induced
hypothermia in mice.
(A) Shown is the effect of treatment with the α2-adrenoceptor agonist Clonidine or the
α2-adrenoceptor antagonist Yohimbine on body temperature measured 30 min after
drug injection. Yohimbine mirrors the effect of PDE4 inhibitors on the duration of
Ketamine/Xylazine anesthesia but does replicate the effect of PDE4 inhibitors in
inducing hypothermia. (B) Neither pretreatment with the α2-adrenoceptor agonist
Clonidine nor the α2-adrenoceptor antagonist Yohimbine protects from PDE4 inhibitorinduced hypothermia Data represent the mean ± SEM.
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DISCUSSION
Literature discussion
The adverse side effects of cAMP-phosphodiesterase 4 enzyme inhibitors, which
includes nausea, emesis, weight loss, and diahrrea have been well recorded. Nausea is a
feeling of gastric discomfort in the stomach and emesis is a neural reflex and are
therefore distinct phenomena. Nausea and emesis both occured at a high prevalence in
clinical trials of 2 FDA approved PDE4 inhibitors – Roflumilast and Apremilast. Despite
billions of dollars of research investment into PDE4 inhibitors, only 3 PDE4 inhibitors
have been developed and approved by the FDA for use in humans for 2 conditions –
COPD (chronic obstructive pulmonary disease) and plaque psoriasis. This is significant
for future PDE4 drug development as a high prevalence of side effects that may make the
patient experience greater discomfort greatly diminishes the clinical utility of a drug.
Through extensive literature research, it has been established that hypothermia
and nausea parallel each other in several paradigms. The evidence of different forms of
nausea and emesis being linked to hypothermia or symptoms of hypothermia shows
promise in establishing a correlate between hypothermia and nausea. In cases of
hypothermia, nausea and emesis are commonly reported side effects. Further, drug- and
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anesthesia-induced nausea and hypothermia occur quite frequently, especially in cases of
post-operative nausea and vomiting (PONV). Finally, the causes of nausea and
hypothermia induced by motion sickness are being studied extensively. Mechanisms that
facilitate the loss of body heat through the skin like cutaneous vasodilation and sweating
are thought to aid in the manifestation of these symptoms. A study cited previously tested
the prevalence of thermoregulatory changes in response to motion-sickness-induced
nausea:
“Similarity between temperature changes elicited by provocative motion in
humans, rats and shrews suggests that these mammalian species possibly possess
similar neural mechanisms linking nausea to thermoregulation. Consequently,
thermoregulatory disturbances may not only be considered as a key
accompanying symptom of nausea, but in fact could be used as a valuable
physiological correlate of this disorder in experimental animals (Ngampramuan et
al., 2014).”
Thus, the literature supports the hypothesis and confirms that hypothermia may represent
a correlate of PDE4 inhibitor-induced in mice.

Experimental discussion
Despite the inability of mice to quantify their nausea and experience emesis, a
correlate has already been established involving PDE4 subtypes and emesis. Robichaud
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and colleagues established PDE4D as the subtype involved in mediating emesis and
nausea. The baseline duration of anesthesia for the PDE4DKO mice was lower than that
of the PDE4WT mice and PDE4BKO mice. This suggests that PDE4D is the subtype that
mediates emesis and nausea, as even with only the ketamine/xylazine anesthesia, they
slept for under 20 minutes. With these findings, Robichaud and colleagues determined
that PDE4D is the subtype that should not be targeted with a future PDE4 inhibitor in
order to extract the therapeutic effects from the adverse side effects.
However, the researchers acknowledged that this link between emesis and PDE4D
was a correlation and that there are other possible explanations for this phenomenon to
occur. One of those explanations is that the anesthetized PDE4D knockout mice likely
have other mechanisms activated in the emesis centers of the brain that would cause them
to experience emesis at a higher rate than the other types of mice (Robichaud et al.,
2002b). Thus, the validity of this study in predicting the role of the PDE4 isoforms in
inducing emesis in humans is yet to be established.
The data in this paper extend the premise that PDE4D mediates emesis to argue
that using the Robichaud, or sleep study correlate, not only does PDE4D mediate emesis,
it is the only PDE4 subtype to do so (Figure 10). After measuring the time to righting (or
duration of anesthesia) of WT mice and KO mice of each subtype, it is clear that PDE4D
has a significantly lower duration of anesthesia when compared to all three of the other
subtypes.
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When comparing the effects of α2-adrenoceptor agonism and antagonism to PDE4
inhibition, it was shown the PDE4 inhibition has similar effects on duration of anesthesia
as antagonism of the α2-adrenoceptor. Therefore, a correlation was established between
the PDE4D subtype identified earlier as the mediator of emesis and duration of
anesthesia.

Hypothermia
Phosphodiesterase 4 inhibitors have been shown to cause a dramatic, quick onset
hypothermia in mice across several genotypes – WT, PDE4AKO, PDE4BKO,
PDE4CKO, and PDE4DKO. It has been proven to be a class effect of PDE4 inhibitors
specifically. None of the PDE4KO mouse lines have a baseline temperature that is
naturally colder than any other or prevents PDE4 inhibitor-induced hypothermia. These
data suggest that hypothermia results from the concurrent inhibition of multiple PDE4
subtypes. This can be deduced because if a single PDE4 subtype were involved in
mediating hypothermia, ablation of that single subtype would lead to a lower baseline
temperature in a PDE4KO mouse than in a wild-type mouse or than the other subtype’s
KO mice. This conclusion is in contrast to the previously established paradigm set by the
sleep study that inactivation of PDE4D is what causes nausea and emesis.
This project attempted to discover whether there was a relation between the sleep
study, which found that α2-adrenoceptor signaling was correlated with PDE4 inhibitorinduced nausea and emesis through PDE4D, and hypothermia induced by PDE4
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inhibitors. In the sleep study, the antagonist MK-912 caused the animal to experience
emesis and shortens the duration of anesthesia, and the same was true for the PAN-PDE4
inhibitor PMNPQ. When replicated in the hypothermia study, the α2-adrenoceptor
antagonist Yohimbine did not elicit a hypothermic effect, whereas the PDE4 inhibitor
Piclamilast did. This is where the two models begin to come apart. Interestingly, it is
treatment with the α2-adrenoceptor agonist clonidine, not the antagonist, that causes
hypothermia in the mouse. Further, pre-treatment of neither the agonist nor antagonist
protects or prevents the mouse from PDE4 inhibitor-induced hypothermia.
This is why we have come to different conclusions about PDE4D. At the
molecular level, PDE4 inhibition and α2-adrenoceptor signaling in sleep time and
hypothermia are completely unrelated. Signaling of the α2-adrenoceptor pathway in the
sleep model is completely independent of the effect of α2-adrenoceptor signaling on
hypothermia. Therefore, these two correlates have nothing to do with each other.
The experimental data from this project testing hypothermia as a correlate of
PDE4 inhibitor-induced nausea supports the hypothesis, however there are some
limitations. Until a PDE4D subtype-selective inhibitor is developed and tested in humans
and proven to not be emetic, there is no hard proof that PDE4D is not the only subtype
involved in mediating emesis. Eventual development of a PDE4D selective inhibitor and
subsequent clinic trials is necessary to confirm the hypothesis.
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CONCLUSIONS
Hypothermia is a class effect of non-selective PDE4 inhibitors. My research
shows that across many models and many species, hypothermia always parallels the
appearance of nausea and emesis which does suggest that this is a useful correlate. A
previous correlate by Robichaud and colleagues identified PDE4D as the PDE4 subtype
involved in mediating emesis and nausea, and therefore, should not be targeted when
developing future PDE4 inhibitors. This was established through the α2-adrenoceptor
signaling pathway where the α2-adrenoceptor antagonist and PDE4 inhibitor had the same
effect of inducing emesis. In the hypothermia model of this project, the α2-adrenoceptor
antagonist and PDE4 inhibitor did not have the same effect. Interestingly, treatment with
the α2-adrenoceptor agonist was responsible for inducing hypothermia, leading to the
conclusion that α2-adrenoceptor signaling in the sleep model and in the hypothermia
model are completely unrelated. If mice are experimented upon that have had each
subtype of PDE4 ablated, we show that none of the knockout mice is naturally
hypothermic. However, all of the PDE4KO mice experience hypothermia when injected
with a PDE4 inhibitor which means simultaneous inhibition of all four PDE4 subtypes is
responsible for inducing hypothermia and therefore, nausea and emesis. For drug
development, this is promising because it means you can target each subtype of PDE4
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individually including PDE4D. This is opposite to the previous paradigm of the
Robichaud sleep experiment which suggested that only PDE4D mediated emesis and
could not be targeted therapeutically.
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